What BMI do you need for Wegovy under BCBS Minnesota?

For weight loss on Employer / Commercial Insurance plans, BCBS Minnesota requires a BMI of 30 or higher, or 27 or higher with a qualifying weight-related condition.

How long does a Wegovy approval last with BCBS Minnesota?

Initial approvals last 12 months, and renewals are granted in 12-month periods.

What does BCBS Minnesota require to renew Wegovy?

At least 5% weight loss from the starting weight, at least 5% reduction in BMI, For adults: weight loss >= 5% from baseline (prior to initiation of pharmacotherapy). For pediatric (12-17): BMI reduction >= 5% from baseline. Exception: if patient has received less than 52 weeks of therapy on the maximum-tolerated dose, continuation is approved without the weight loss threshold. Renewal also requires dose be 1.7 mg, 2.4 mg, or 25 mg. Patient must maintain diet/exercise/behavioral modification regimen and not combine with another weight loss agent or GLP-1, at least 52 weeks on therapy before the first renewal, and staying on a maintenance dose of at least 1.7 mg.

What if my plan excludes weight loss medications?

BCBS Minnesota has separate Wegovy policies for heart disease risk reduction and liver disease (mash), which are covered on some plan types and don't depend on the weight-loss benefit. Wegovy is also available for cash through NovoCare.

How current is this information?

This page reflects BCBS Minnesota's written policy as of April 1, 2026, last verified against the source document on June 5, 2026.

BCBS Minnesota

Does BCBS Minnesota cover Wegovy?

Quick answer · Weight Loss

BCBS Minnesota covers it only when the plan's benefit includes it on Employer / Commercial Insurance.

Employer / Commercial Insurance: Depends on your plan's benefit. Weight loss must NOT be excluded from coverage under the patient's pharmacy benefit. Applies to FlexRx Closed, FlexRx Open, GenRx Closed, and GenRx Open for weight loss agents on coverage delay.

Last verified June 5, 2026. Policy effective April 1, 2026. Source: Pa policy. How we verify this data →

Check your card for your exact plan →

Wegovy for Weight Loss

What BCBS Minnesota requires, by plan type. Open this indication on its own page →

Employer / Commercial Insurance

Depends on your plan's benefit

Weight loss must NOT be excluded from coverage under the patient's pharmacy benefit. Applies to FlexRx Closed, FlexRx Open, GenRx Closed, and GenRx Open for weight loss agents on coverage delay.

What you need to qualify

Age 12 and older
BMI of 30 or higher
BMI of 27 or higher with a weight-related condition (HTN, T2DM, OSA, CVD, and dyslipidemia)
BMI of 25 or higher for patients of Asian descent
BMI at or above the 95th percentile for age and sex
6 months of a documented diet and exercise program

Qualification pathways

You can qualify through any one of these.

Adult Weight Management

All of:

Weight loss is NOT excluded from coverage under the patient's pharmacy benefit
Patient is new to therapy, not previously approved by Prime, or attempting a repeat weight loss course
Patient is an adult (18 years of age or over)
Patient has been on a low-calorie diet, increased physical activity, and behavioral modifications for a minimum of 6 months
Patient experienced weight loss of less than 1 pound per week on weight management regimen prior to any pharmacotherapy
Patient will NOT use the requested agent in combination with another weight loss agent (e.g., Contrave, phentermine, Qsymia, Xenical)
Patient is currently on and will continue weight management regimen (low-calorie diet, increased physical activity, behavioral modifications)
Patient will NOT use the requested agent in combination with another GLP-1 receptor agonist
Patient does NOT have any FDA labeled contraindications to the requested agent
Patient's age is within FDA labeling OR there is support for use at patient's age
Patient has tried and failed at least three formulary alternatives OR prescriber indicates alternatives are contraindicated, likely less effective, or likely to cause adverse reaction

Plus any one of:

BMI >= 30 kg/m2
BMI >= 25 kg/m2 if patient is of South Asian, Southeast Asian, or East Asian descent
BMI >= 27 kg/m2 with at least one weight-related comorbidity/risk factor/complication (e.g., hypertension, T2DM, OSA, CVD, dyslipidemia)

Pediatric Weight Management (12-17 years)

All of:

Weight loss is NOT excluded from coverage under the patient's pharmacy benefit
Patient is new to therapy, not previously approved by Prime, or attempting a repeat weight loss course
Patient is pediatric (12 to 17 years of age)
Patient has been on a low-calorie diet, increased physical activity, and behavioral modifications for a minimum of 6 months
Patient experienced weight loss of less than 1 pound per week on weight management regimen prior to any pharmacotherapy
Patient will NOT use the requested agent in combination with another weight loss agent
Patient is currently on and will continue weight management regimen
Patient will NOT use the requested agent in combination with another GLP-1 receptor agonist
Patient does NOT have any FDA labeled contraindications
Patient's age is within FDA labeling OR there is support for use at patient's age
Patient has tried and failed at least three formulary alternatives OR prescriber indicates alternatives are contraindicated, likely less effective, or likely to cause adverse reaction

Plus any one of:

BMI >= 95th percentile for age and sex
BMI >= 30 kg/m2
BMI >= 85th percentile for age and sex AND at least one severe weight-related comorbidity/risk factor/complication (e.g., hypertension, dyslipidemia, T2DM, OSA)

Repeat Course of Therapy (prior weight loss agent in past 12 months)

All of:

Patient has tried a targeted weight loss agent for a previous course of therapy in the past 12 months
Prescriber anticipates success with repeating therapy with any targeted weight loss agent
All other standard weight management criteria met

Documentation to bring

Documentation of BMI (>= 30 kg/m2, or >= 27 kg/m2 with comorbidity, or >= 25 kg/m2 if South/Southeast/East Asian)
Documentation of 6-month weight management regimen (low-calorie diet, increased physical activity, behavioral modifications)
Documentation of weight loss less than 1 pound per week on weight management regimen prior to pharmacotherapy
Documentation that weight loss is not excluded from coverage under the patient's pharmacy benefit
Documentation of formulary alternatives tried and failed (at least 3), or clinical reason alternatives are contraindicated/less effective/harmful
For pediatric patients: documentation of age (12-17), BMI percentile for age and sex, and qualifying comorbidities if applicable
For repeat course: documentation of prior targeted weight loss agent use and prescriber attestation of anticipated success

Approval and renewal

Initial approval: 12 months
Renewal: every 12 months
To renew, the plan looks for at least 5% weight loss from the starting weight, at least 5% reduction in BMI, For adults: weight loss >= 5% from baseline (prior to initiation of pharmacotherapy). For pediatric (12-17): BMI reduction >= 5% from baseline. Exception: if patient has received less than 52 weeks of therapy on the maximum-tolerated dose, continuation is approved without the weight loss threshold. Renewal also requires dose be 1.7 mg, 2.4 mg, or 25 mg. Patient must maintain diet/exercise/behavioral modification regimen and not combine with another weight loss agent or GLP-1, at least 52 weeks on therapy before the first renewal, and staying on a maintenance dose of at least 1.7 mg. Make sure your starting weight and date are in the chart now — renewal is measured against it.

Not covered when

Co-administration with another weight loss agent (e.g., Contrave, phentermine, Qsymia, Xenical) is not permitted
Co-administration with another GLP-1 receptor agonist is not permitted
Any FDA labeled contraindications to the requested agent
Weight loss coverage excluded from pharmacy benefit

Policy note: Policy applies to FlexRx Closed, FlexRx Open, FocusRx, GenRx Closed, GenRx Open, Health Insurance Marketplace, and KeyRx formularies. Weight loss agents on coverage delay apply to FlexRx Closed, FlexRx Open, GenRx Closed, and GenRx Open. For the 6-month lifestyle program, the patient must not have lost >= 1 lb/week (i.e., inadequate response to lifestyle). The initial approval criteria for Wegovy weight loss specifically include continuation milestones embedded: starting therapy or < 52 weeks of therapy are eligible without weight loss threshold; >= 52 weeks requires >= 5% weight loss. Prior targeted weight loss agent (Saxenda, Wegovy, Zepbound) use in the past 12 months does not automatically disqualify but requires prescriber attestation. Managed by Prime Therapeutics.

Policy effective April 1, 2026 · verified June 5, 2026 · source: Pa policy

Wegovy for Heart Disease Risk Reduction

What BCBS Minnesota requires, by plan type. Open this indication on its own page →

Employer / Commercial Insurance

Depends on your plan's benefit

Expanded indications must NOT be restricted from coverage under the patient's pharmacy benefit.

What you need to qualify

Age 45 and older
BMI of 27 or higher
Prescribed by or in consultation with a specialist
Established cardiovascular disease (MI, stroke, and PAD)
On guideline-directed medical therapy (ACE_inhibitor, ARB, beta_blocker, statin, and ezetimibe)
Not being used to treat type 1 diabetes

Qualification pathways

You can qualify through any one of these.

CV Risk Reduction — Initial Approval

All of:

Expanded indications are NOT restricted from coverage under the patient's pharmacy benefit
Requested agent is FDA labeled for the requested indication and route of administration (Wegovy)
Patient has a BMI >= 27 kg/m2
Patient does NOT have type 2 diabetes
Patient's age is 45 years or over
Patient is currently being treated in the past 90 days with antihypertensive therapy (ACE inhibitor, ARB, or beta blocker)
Patient is currently being treated in the past 90 days with lipid lowering therapy (any statin or ezetimibe)
Patient will continue antihypertensive therapy AND lipid lowering therapy in combination with the requested agent
Prescriber is a specialist (e.g., cardiologist) or has consulted with a specialist
Patient will NOT use the requested agent in combination with another weight loss agent
Patient is currently on and will continue weight management regimen (low-calorie diet, increased physical activity, behavioral modifications)
Patient will NOT use the requested agent in combination with another GLP-1 receptor agonist
Patient does NOT have any FDA labeled contraindications
Patient has tried and failed at least three formulary alternatives OR prescriber indicates alternatives are contraindicated, likely less effective, or likely to cause adverse reaction

Plus any one of:

History of myocardial infarction
History of stroke
Peripheral artery disease defined by intermittent claudication with ankle-brachial index < 0.85 at rest, or peripheral arterial revascularization procedure, or amputation due to atherosclerotic disease

Tobacco Use Requirement

Plus any one of:

Patient does NOT currently use any tobacco products (cigarettes, chewing tobacco)
Patient is being managed for tobacco cessation

Documentation to bring

Medical records documenting established cardiovascular disease (CAD, ACS, history of MI, angina, revascularization, PCI/CABG, stroke, TIA, carotid or arterial stenosis, PAD including aortic aneurysm, all of atherosclerotic origin)
Medical records confirming qualifying CV event: MI, stroke, or PAD (intermittent claudication with ABI < 0.85, peripheral arterial revascularization, or amputation due to atherosclerotic disease)
Documentation of BMI >= 27 kg/m2
Documentation that patient does NOT have type 2 diabetes
Documentation that patient is age 45 or over
Documentation of current antihypertensive therapy (ACE inhibitor, ARB, or beta blocker) within past 90 days
Documentation of current lipid-lowering therapy (statin or ezetimibe) within past 90 days
Documentation of tobacco use status or active tobacco cessation management
Documentation of specialist involvement (cardiologist) or consultation
Documentation of formulary alternatives tried and failed (at least 3), or clinical reason alternatives are contraindicated/less effective/harmful

Approval and renewal

Initial approval: 12 months
Renewal: every 12 months
To renew, the plan looks for At renewal: patient must have clinical benefit with the requested agent. CV qualifying event and T2DM exclusion are re-verified at renewal. GDMT requirement at renewal is slightly relaxed: patient must be treated with antihypertensive therapy AND/OR lipid-lowering therapy (initial approval requires BOTH antihypertensive AND lipid-lowering therapy). Tobacco cessation requirement is re-verified. Specialist requirement is re-verified.

Not covered when

Type 2 diabetes (explicitly excluded — this indication requires absence of T2DM)
Co-administration with another weight loss agent (e.g., Contrave, phentermine, Qsymia, Xenical)
Co-administration with another GLP-1 receptor agonist
Any FDA labeled contraindications

Policy note: Established CVD is broadly defined in this policy to include: CAD, ACS, history of MI, stable or unstable angina, coronary or other arterial revascularization, prior PCI/CABG, stroke, TIA, carotid or other arterial stenosis, or PAD including aortic aneurysm (all of atherosclerotic origin). However, for the qualifying CV event (criteria #3), only MI, stroke, or PAD (as specifically defined) qualify. At renewal, GDMT requirement is slightly relaxed from 'both antihypertensive AND lipid-lowering' to 'antihypertensive AND/OR lipid-lowering.' Managed by Prime Therapeutics.

Policy effective April 1, 2026 · verified June 5, 2026 · source: Pa policy

Wegovy for Liver Disease (MASH)

What BCBS Minnesota requires, by plan type. Open this indication on its own page →

Employer / Commercial Insurance

Depends on your plan's benefit

Expanded indications must NOT be restricted from coverage under the patient's pharmacy benefit.

What you need to qualify

Age 18 and older
Prescribed by or in consultation with a specialist
Confirmed MASH diagnosis by liver_biopsy, FibroScan_VCTE, ELF_test, and MRE, fibrosis stage F2 to F3

Qualification pathways

You can qualify through any one of these.

MASH with F2-F3 Fibrosis — Initial Approval

All of:

Expanded indications are NOT restricted from coverage under the patient's pharmacy benefit
Diagnosis of noncirrhotic MASH (formerly NASH) with moderate to advanced liver fibrosis (stages F2 to F3)
Requested agent is Wegovy injection
Patient is an adult (18 years of age or over)
Stage F2 or F3 fibrosis confirmed by one of: liver biopsy, VCTE (e.g., FibroScan), ELF score, or MRE (prior to therapy)
Patient is being monitored and/or treated for any comorbid conditions (e.g., cardiovascular disease, diabetes, dyslipidemia, hypertension)
Patient does NOT have decompensated cirrhosis
Patient does NOT have moderate to severe hepatic impairment (Child-Pugh Class B or C)
Patient does NOT have any other liver disease (e.g., Wilson's disease, HCC, hepatitis)
Prescriber is a specialist (e.g., hepatologist, gastroenterologist) or has consulted with a specialist
Patient will NOT use the requested agent in combination with another weight loss agent
Patient is currently on and will continue weight management regimen
Patient will NOT use the requested agent in combination with another GLP-1 receptor agonist
Patient does NOT have any FDA labeled contraindications
Patient has tried and failed at least three formulary alternatives OR prescriber indicates alternatives are contraindicated, likely less effective, or likely to cause adverse reaction

Plus any one of:

Female patient with alcohol consumption less than 20 grams/day
Male patient with alcohol consumption less than 30 grams/day

Documentation to bring

Medical records documenting diagnosis of noncirrhotic MASH with fibrosis stages F2 or F3
Documentation of fibrosis staging confirmed by liver biopsy, VCTE (FibroScan), ELF score, or MRE (obtained prior to therapy initiation)
Documentation of alcohol consumption (< 20 g/day for females; < 30 g/day for males)
Documentation of monitoring/treatment for comorbid conditions (CVD, diabetes, dyslipidemia, hypertension)
Documentation ruling out decompensated cirrhosis, Child-Pugh Class B or C hepatic impairment, and other liver diseases (Wilson's disease, HCC, hepatitis)
Documentation of specialist involvement (hepatologist or gastroenterologist) or consultation
Documentation of formulary alternatives tried and failed (at least 3), or clinical reason alternatives are contraindicated/less effective/harmful

Approval and renewal

Initial approval: 12 months
Renewal: every 12 months
To renew, the plan looks for At renewal: patient must have clinical benefit with the requested agent. Alcohol limits (< 20 g/day female, < 30 g/day male) are re-verified. Exclusions for decompensated cirrhosis, Child-Pugh B/C, and other liver disease are re-verified. Specialist requirement is re-verified. Fibrosis staging confirmation (liver biopsy/VCTE/ELF/MRE) is NOT re-required at renewal.

Not covered when

Decompensated cirrhosis
Moderate to severe hepatic impairment (Child-Pugh Class B or C)
Any other liver disease (e.g., Wilson's disease, hepatocellular carcinoma, hepatitis)
Co-administration with another weight loss agent
Co-administration with another GLP-1 receptor agonist
Any FDA labeled contraindications
Alcohol consumption >= 20 g/day (female) or >= 30 g/day (male)

Policy note: The MASH indication is an expanded indication. Fibrosis must be stage F2 or F3 (noncirrhotic). Fibrosis confirmation methods accepted: liver biopsy, VCTE (FibroScan), ELF score, or MRE — no lookback period explicitly stated in the policy. The policy does not explicitly state a FIB-4 score as a standalone qualifying confirmation method (though it is discussed in the clinical rationale). The policy requires monitoring/treatment of comorbidities. Alcohol limits align with MASLD definition: < 20 g/day female, < 30 g/day male. Managed by Prime Therapeutics.

Policy effective April 1, 2026 · verified June 5, 2026 · source: Pa policy

Why Wegovy requests get denied by BCBS Minnesota

Based on what this policy asks for. Fix these before the first submission.

Your specific plan doesn't include the weight loss benefit. Coverage here is conditional on the benefit design (often an optional employer add-on), so confirm it before submitting.
Wrong brand for the diagnosis. Wegovy and Ozempic are the same molecule with different approved uses; a request for Wegovy under a diagnosis that matches Ozempic is routinely denied.
BMI not documented in the chart notes (or documented without a baseline weight and date).
Qualifying weight-related condition not documented with its own diagnosis code.
No documented diet and exercise program.
Prescriber isn't the specialist the plan requires.
Baseline weight wasn't recorded at the start, so the required weight loss can't be shown at renewal.

If weight loss isn't covered on your plan

BCBS Minnesota has separate Wegovy policies that don't depend on the weight loss benefit:

Heart Disease Risk Reduction — covered on Employer / Commercial Insurance.
Liver Disease (MASH) — covered on Employer / Commercial Insurance.

Wegovy is also sold directly by Novo Nordisk without insurance through NovoCare.

Frequently asked questions

Does BCBS Minnesota cover Wegovy?: BCBS Minnesota covers it only when the plan's benefit includes it on Employer / Commercial Insurance.
What BMI do you need for Wegovy under BCBS Minnesota?: For weight loss on Employer / Commercial Insurance plans, BCBS Minnesota requires a BMI of 30 or higher, or 27 or higher with a qualifying weight-related condition.
How long does a Wegovy approval last with BCBS Minnesota?: Initial approvals last 12 months, and renewals are granted in 12-month periods.
What does BCBS Minnesota require to renew Wegovy?: At least 5% weight loss from the starting weight, at least 5% reduction in BMI, For adults: weight loss >= 5% from baseline (prior to initiation of pharmacotherapy). For pediatric (12-17): BMI reduction >= 5% from baseline. Exception: if patient has received less than 52 weeks of therapy on the maximum-tolerated dose, continuation is approved without the weight loss threshold. Renewal also requires dose be 1.7 mg, 2.4 mg, or 25 mg. Patient must maintain diet/exercise/behavioral modification regimen and not combine with another weight loss agent or GLP-1, at least 52 weeks on therapy before the first renewal, and staying on a maintenance dose of at least 1.7 mg.
What if my plan excludes weight loss medications?: BCBS Minnesota has separate Wegovy policies for heart disease risk reduction and liver disease (mash), which are covered on some plan types and don't depend on the weight-loss benefit. Wegovy is also available for cash through NovoCare.
How current is this information?: This page reflects BCBS Minnesota's written policy as of April 1, 2026, last verified against the source document on June 5, 2026.

Other medications under BCBS Minnesota

Wegovy coverage under other plans

All insurance plans · All medications

This page summarizes BCBS Minnesota's written prior-authorization policy. It is not a guarantee of coverage; plans vary by employer and benefit design. Verify with your plan before relying on it.